Incyte Corporation

Incyte Corporation is a biopharmaceutical company headquartered in Wilmington, Delaware, founded in 1991. Its shares trade on Nasdaq under the ticker INCY, and it is a member of the S&P 500 index. The company develops and markets medicines for cancer and for diseases driven by the immune system.

Most of its income comes from Jakafi, used in bone marrow diseases and graft-versus-host disease; the same active ingredient is sold outside the United States by Novartis under the name Jakavi, and Incyte receives royalties from those sales. Opzelura is a cream used in skin diseases such as atopic dermatitis and vitiligo. Zynyz is an immunotherapy medicine used in some types of cancer. The research pipeline includes candidates being studied for blood cancers, solid tumors and inflammatory skin diseases. Besides its products, the company also earns income from collaborations with other drug companies.

Those following Incyte stock typically track clinical trial results, developments on patent terms, the approval timetable for new medicines and drug pricing regulation. On the INCY page at Lzzo.com the price is shown in US dollars, and a price chart and technical indicators appear on the same page.